Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.29B | 17.60B | 15.56B | 12.73B | 13.53B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.29B | 17.60B | 15.56B | 12.73B | 13.53B |
| Cost of Revenue | 3.37B | 3.01B | 2.45B | 2.22B | 2.40B |
| Gross Profit | 15.92B | 14.59B | 13.11B | 10.50B | 11.13B |
| SG&A Expenses | 3.46B | 2.63B | 2.65B | 2.36B | 2.77B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.63B | 9.10B | 8.43B | 7.32B | 8.20B |
| Operating Income | 8.66B | 8.50B | 7.13B | 5.41B | 5.34B |
| Income Before Tax | 8.27B | 7.23B | 6.78B | 3.46B | 5.04B |
| Income Tax Expenses | 1.63B | 1.65B | 1.12B | 696.80M | 628.50M |
| Earnings from Continuing Operations | 6.64B | 5.58B | 5.66B | 2.76B | 4.41B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.64B | 5.58B | 5.66B | 2.76B | 4.41B |
| EBIT | 8.66B | 8.50B | 7.13B | 5.41B | 5.34B |
| EBITDA | 9.25B | 8.97B | 7.60B | 5.87B | 5.82B |
| EPS Basic | 7.39 | 6.22 | 6.30 | 3.07 | 4.88 |
| Normalized Basic EPS | 6.19 | 5.72 | 4.74 | 3.62 | 3.84 |
| EPS Diluted | 7.39 | 6.21 | 6.29 | 3.06 | 4.88 |
| Normalized Diluted EPS | 6.19 | 5.71 | 4.73 | 3.62 | 3.84 |
| Average Basic Shares Outstanding | 898.00M | 896.90M | 897.90M | 898.70M | 903.16M |
| Average Diluted Shares Outstanding | 898.00M | 898.80M | 899.80M | 900.60M | 903.16M |
| Dividend Per Share | 1.50 | 1.50 | 1.50 | 1.50 | 1.30 |
| Payout Ratio | 20.27% | 24.10% | 23.80% | 48.79% | 26.48% |